Alex Hongsheng Chang

10PUBLICATIONS
36CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 08, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T-Treated T-cell Lymphoid Malignancies.

|Jul 03, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|Feb 27, 2026
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Wenqiang Yan, Chenxing Du, Rui Lv

|Sep 24, 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.

Jingjing Feng, Dawei Huo, Ruimin Hong

|Apr 24, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Yinqiang Zhang, Chenggong Li, Mengyi Du

|Mar 07, 2023
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.

Jieyun Xia, Hujun Li, Zhiling Yan

Pageof 2

Frequent Collaborators

6 joint publications

He Huang

4 joint publications

Yongxian Hu

2 joint publications

Jingjing Li

2 joint publications

Marcel R M van den Brink